March 26, 2024 | Press Release
MINNEAPOLIS — Today the U.S. Supreme Court heard oral arguments in FDA v. Alliance for Hippocratic Medicine and Danco v. Alliance for Hippocratic Medicine, cases brought by health care professionals arguing that the FDA illegally approved and then expanded access to the abortion drug mifepristone at the expense of women’s safety. MCCL Co-Executive Director Cathy Blaeser issued the following statement:
“The Biden administration has rolled back longstanding safety protocols surrounding mifepristone, and pregnant women are the ones paying the price. Research shows that chemical abortions are four times riskier than surgical ones. And the risks only increase when the drug is sent through the mail without a doctor’s visit. We hope that the Court will recognize these dangers and act in the best interest of women and their unborn children.”
For additional information about the risks of chemical abortions, see Dr. Randall O’Bannon's recent article on the complication rates of mifepristone. See also National Right to Life's white paper What the Media Missed in Its Coverage of the U.S. Fifth Circuit Court of Appeals Decision Regarding Mifepristone.